A5069675533- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Risks and Factors
- Advanced Radiotherapy Techniques
- Health Systems, Economic Evaluations, Quality of Life
- Urological Disorders and Treatments
- Urinary Bladder and Prostate Research
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- Genital Health and Disease
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
- Patient-Provider Communication in Healthcare
- Advanced Chemical Sensor Technologies
- Cancer survivorship and care
- Sexual function and dysfunction studies
- Urologic and reproductive health conditions
- Viral-associated cancers and disorders
- Nutrition and Health in Aging
- Multiple and Secondary Primary Cancers
- Bayesian Modeling and Causal Inference
- Patient Satisfaction in Healthcare
- Inflammatory Biomarkers in Disease Prognosis
- Clinical practice guidelines implementation
Maastricht University
2017-2024
Maastricht University Medical Centre
2015-2024
Maasstad Ziekenhuis
2023
Utrecht University
2009-2011
Radboud University Nijmegen
2001-2011
Catharina Ziekenhuis
2010-2011
The Netherlands Cancer Institute
2011
University Medical Center Utrecht
2009-2011
Radboud University Medical Center
2001-2009
Canisius-Wilhelmina Ziekenhuis
2005
Prognostic (case series).4. What's known on the subject? and What does study add? Nowadays more publications have been published about topic prostate cancer aggressiveness obesity with mixed results. However, most of used BMI as a marker for obesity, while metabolic active fat is visceral fat. To learn these relations we measured in our paper.To examine if periprostatic computed tomography (CT) correlates advanced disease examined patients who received radiotherapy localized cancer. Several...
To assess the risk of second primary cancer (SPC) after [(125)I]iodine prostate brachytherapy compared with prostatectomy and general population.In a cohort consisting 1,888 patients who received monotherapy (n = 1,187; 63%) or 701; 37%), SPC incidences were retrieved by linkage Dutch Cancer Registry. Standardized incidence rates (SIRs) absolute excess risks (AERs) calculated for comparison.A total 223 diagnosed SPC, 136 (11%) 87 (12%) prostatectomy, median follow-up 7.5 years. The SIR all...
Patient decision aids (PDAs) can support the treatment making process and empower patients to take a proactive role in their pathway while using shared decision-making (SDM) approach participatory medicine possible. The aim of this study was develop PDA for prostate cancer that is accurate user-friendly. We followed user-centered design consisting five rounds semi-structured interviews usability surveys with topics such as informational/decisional needs users requirements PDAs. Our user-base...
This study aimed to assess the effects of 20 wk resistance exercise training with or without protein supplementation on body composition, muscle mass, strength, physical performance, and aerobic capacity in prostate cancer patients receiving androgen deprivation therapy (ADT).Sixty ADT were randomly assigned perform 31 g whey (EX + PRO, n = 30) placebo PLA, 30), consumed immediately after every night before sleep. A separate control group (CON, 36) only received usual care. At baseline wk,...
European Association of Urology guidelines recommend a risk-adjusted biopsy strategy for early detection prostate cancer in biopsy-naïve men. It remains unclear which is most effective. Therefore, we evaluated two risk assessment pathways commonly used clinical practice.To compare the diagnostic performance risk-based ultrasound (US)-directed pathway (Rotterdam Prostate Cancer Risk Calculator [RPCRC] #3; US volume assessment) and magnetic resonance imaging (MRI)-directed pathway.This was...
Therapeutic efficacy of cisplatin-based treatment late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and to develop new approaches for overcoming resistance, we generated long-term cisplatin treated (LTT) UC cell lines, characterised their response, determined the expression molecules involved in transport detoxification, DNA repair, apoptosis. Inhibitors metallothioneins Survivin were applied investigate ability sensitise towards...
<i>Objective:</i> The increasing incidence of both obesity and prostate cancer (PCa) detection will confront the urologist more often with obese men having PCa. It is unknown whether affects surgical oncological outcomes following open radical retropubic prostatectomy (RRP). Knowledge concerning this issue relevant when counselling patients PCa for RRP. <i>Patients Methods:</i> A single institution cohort study was performed including 252 who underwent a RRP between...
Several reports found that obesity was associated with prostate cancer (PC) aggressiveness among men treated radical prostatectomy or radiotherapy. Studies concerning this issue have basically relied on body mass index (BMI), as a marker for general obesity. Because visceral fat is the most metabolic active fat, we sought to evaluate if periprostatic measured computed tomography (CT) better than BMI predict PC in Dutch population who underwent brachytherapy localized PC.Of 902 patients...
Tumour heterogeneity and resistance to systemic treatment in urothelial carcinoma (UC) may arise from cancer stem cells (CSC). A recent model describes cellular differentiation states within UC based on corresponding expression of surface markers (CD) cytokeratins (CK) with CD90 CK14 positive representing the least differentiated most tumourigenic population. Based fact that this population is postulated constitute CSCs origin cisplatin resistance, we enriched cell lines (UCCs) for studied...
To evaluate guideline adherence and variation in the recommended use of neoadjuvant chemotherapy (NAC) effects this on survival patients with non-metastatic muscle-invasive bladder cancer (MIBC).In nationwide, Netherlands Cancer Registry-based study, we identified 1025 newly diagnosed MIBC between November 2017 2019 who underwent radical cystectomy. Patients ECOG performance status 0-1 creatinine clearance ≥ 50 mL/min/1.73 m2 were considered NAC-eligible. Interhospital was assessed using...
Study Type – Prognosis (case series) Level of Evidence 4 OBJECTIVE To examine the relationship between body mass index (BMI) and biochemical recurrence (BCR), cancer‐specific (CSS) overall survival (OS) in men treated with permanent prostate brachytherapy (PPB), as there is limited information on affect obesity treatment outcomes for cancer. PATIENTS AND METHODS In all, 1530 patients clinically localized cancer who underwent PPB were studied. Clinical pathological data retrospectively...
While the 10-year survival rate for localized prostate cancer patients is very good (>98%), side effects of treatment may limit quality life significantly. Erectile dysfunction (ED) a common burden associated with increasing age as well treatment. Although many studies have investigated factors affecting erectile after treatment, only limited whether ED can be predicted before start The advent machine learning (ML) based prediction tools in oncology offers promising approach to improve...
To investigate whether body mass index (BMI) is a prognostic factor for biochemical recurrence (BCR) in Dutch men after radical prostatectomy (RP), as although epidemiological studies of obesity relation to prostate cancer have provided conflicting results, recent from the USA suggest that higher BMI risk progression cancer.Of 1417 patients with who had RP at two University hospitals, 1302 were included present study. (kg/m(2)) classes defined normal (<25), overweight (25-30) and obese (> or...